ERYCETTE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erycette, and what generic alternatives are available?
Erycette is a drug marketed by Johnson And Johnson and is included in one NDA.
The generic ingredient in ERYCETTE is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erycette
A generic version of ERYCETTE was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for ERYCETTE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 4,188 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ERYCETTE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ERYCETTE
US Patents and Regulatory Information for ERYCETTE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Johnson And Johnson | ERYCETTE | erythromycin | SWAB;TOPICAL | 050594-001 | Feb 15, 1985 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
